{
    "id": "34c615d6-ddc9-c4b5-e063-6294a90a047f",
    "indications": "bortezomib injection proteasome inhibitor indicated : treatment patients multiple myeloma ( 1.1 ) treatment patients mantle cell lymphoma ( 1.2 )",
    "contraindications": "subcutaneous intravenous . route different reconstituted concentration . exercise caution calculating volume administered . ( 2.1 , 2.10 ) recommended starting dose bortezomib injection 1.3 mg/m 2 administered either 3 5 second bolus intravenous injection subcutaneous injection . ( 2.2 , 2.4 , 2.6 ) retreatment multiple myeloma : may retreat starting last tolerated dose . ( 2.6 ) hepatic impairment : lower starting dose patients moderate severe hepatic impairment . ( 2.8 ) dose must individualized prevent overdose ( 2.10 )",
    "warningsAndPrecautions": "bortezomib injection supplied individually cartoned 10 ml vials containing 3.5 mg bortezomib white off-white cake powder . ndc 70069-836-01 3.5 mg single-dose vial",
    "adverseReactions": "bortezomib injection contraindicated patients hypersensitivity ( including local ) bortezomib , boron , mannitol . included anaphylactic [ ( 6.1 ) ] . bortezomib injection contraindicated intrathecal . fatal events occurred intrathecal bortezomib injection .",
    "ingredients": [
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A"
        },
        {
            "name": "TERT-BUTYL ALCOHOL",
            "code": "MD83SFE959"
        },
        {
            "name": "BORTEZOMIB",
            "code": "69G8BD63PP"
        }
    ],
    "organization": "Somerset Therapeutics LLC",
    "name": "Bortezomib",
    "effectiveTime": "20250510",
    "indications_original": "Bortezomib for injection is a proteasome inhibitor indicated for: treatment of patients with multiple myeloma ( 1.1 ) treatment of patients with mantle cell lymphoma ( 1.2 )",
    "contraindications_original": "For subcutaneous or intravenous use only. Each route of administration has a different reconstituted concentration. Exercise caution when calculating the volume to be administered. ( 2.1 , 2.10 ) The recommended starting dose of Bortezomib for Injection is 1.3 mg/m 2 administered either as a 3 to 5 second bolus intravenous injection or subcutaneous injection. ( 2.2 , 2.4 , 2.6 ) Retreatment for multiple myeloma: May retreat starting at the last tolerated dose. ( 2.6 ) Hepatic Impairment: Use a lower starting dose for patients with moderate or severe hepatic impairment. ( 2.8 ) Dose must be individualized to prevent overdose ( 2.10 )",
    "warningsAndPrecautions_original": "Bortezomib for injection is supplied as individually cartoned 10 mL vials containing 3.5 mg of bortezomib as a white to off-white cake or powder.\n                  NDC 70069-836-01\n                  \n                     \n                        3.5 mg single-dose vial",
    "adverseReactions_original": "Bortezomib for injection is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. Reactions have included anaphylactic reactions [\n \n  see\n  \n   Adverse Reactions (6.1)\n                     ].\n\n \n                  Bortezomib for injection is contraindicated for intrathecal administration. Fatal events have occurred with intrathecal administration of bortezomib for injection ."
}